Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

Fig. 6

Effect of refametinib and pictilisib combined treatment with or without trastuzumab in HER2-amplified metastatic colorectal cancer patient derived tumor xenografts. Tumor samples with HER2 amplification derived from three different patients were directly implanted and expanded in mice. a Representative tumor growth curves of tumors in xenopatients derived from quadruple-negative HER2-amplified cases CRC 1432, CRC 130, CRC 0186 treated with the indicated modalities for 5 weeks: trastuzumab 10 mg/kg i.p., twice weekly; refametinib 25 mg/kg by o.g., daily; pictilisib 75 mg/kg by o.g., daily. b Histogram represents the tumor volume of each treatment compared to the maximum growth of the control at the fourth week

Back to article page